Innate Pharma (NASDAQ:IPHA) Shares Up 4.4% – Here’s What Happened

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) rose 4.4% on Tuesday . The company traded as high as $1.9574 and last traded at $1.89. Approximately 11,716 shares were traded during trading, a decline of 71% from the average daily volume of 40,569 shares. The stock had previously closed at $1.81.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on IPHA. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Innate Pharma in a research report on Tuesday, April 7th. Weiss Ratings lowered Innate Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Finally, BTIG Research started coverage on Innate Pharma in a research report on Thursday, March 12th. They issued a “buy” rating and a $8.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Innate Pharma Trading Up 4.4%

The business has a fifty day simple moving average of $1.69 and a 200-day simple moving average of $1.67.

Innate Pharma (NASDAQ:IPHA) last announced its quarterly earnings data on Saturday, February 14th. The company reported ($0.18) EPS for the quarter. The firm had revenue of $2.41 million for the quarter. On average, sell-side analysts anticipate that Innate Pharma S.A. Sponsored ADR will post -0.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Innate Pharma

A number of large investors have recently bought and sold shares of the stock. Jane Street Group LLC bought a new stake in Innate Pharma in the fourth quarter valued at $162,000. OLD Mission Capital LLC acquired a new position in shares of Innate Pharma during the fourth quarter valued at about $50,000. Finally, Millennium Management LLC bought a new position in shares of Innate Pharma during the 4th quarter worth about $36,000. 0.16% of the stock is currently owned by institutional investors and hedge funds.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.